Evaluation of the therapeutic efficacy of Vitex agnus-castus extract on cisplatin-induced hematotoxicity in female Wistar rats
-
Published:2023-11
Issue:
Volume:
Page:2186-2191
-
ISSN:2231-0916
-
Container-title:Veterinary World
-
language:en
-
Short-container-title:Vet World
Author:
Tripathy Aparna1ORCID, Raghavendra Archana Parampalli1ORCID, Dutta Babi2ORCID, Surendran Sudarshan3ORCID
Affiliation:
1. Division of Physiology, Department of Basic Medical Sciences, MAHE, Manipal, Karnataka, India. 2. Division of Biochemistry, Department of Basic Medical Sciences, MAHE, Manipal, Karnataka, India. 3. Department of Clinical Anatomy and Medical Imaging, American University of Antigua College of Medicine, Antigua.
Abstract
Background and Aim: Cisplatin (CP) is a preferred drug for cancer treatment but it has dose-dependent side effects. Vitex agnus-castus (VAC) berry extract has antioxidant, free-radical scavenging, and anti-inflammatory activities. This study explored the mitigating effects of VAC extract (VACE) on acute hematotoxicity induced by CP in female Wistar rats.
Materials and Methods: Female Wistar rats (n = 30) were randomly divided into five groups (n = 6/group). The normal control (NC) group received no treatment. The CP control group received CP (7 mg/kg.b.w. ip, single dose) and the drug control group (VACE-650) received VACE (650 mg/kg b.w. oral, daily) for 7 days. Both groups received a single dose of CP (7 mg/kg b.w. ip), followed by 350 and 650 mg/kg.b.w. of VACE daily orally (CPVACE-350 and CPVACE-650 groups, respectively) for 7 days.
Results: After a single dose of CP (7 mg/kg b.w.), the red blood cells (RBC), hematocrit (HCT), white blood cells (WBC), and platelets significantly decreased. In the VAC-350 group, the reduction in total WBC count was less than that in the VAC-650 group on the 3rd day. The RBC and HCT values of the VACE groups were better than that of the CP control, but the VACE-350 treatment group showed significant improvement only on the 3rd day.
Conclusion: Our findings showed that VACE can mitigate CP-induced damage to peripheral blood cells at lower doses.
Keywords: cisplatin, hematotoxicity, rats, Vitex agnus-castus.
Funder
Manipal Academy of Higher Education
Publisher
Veterinary World
Subject
General Veterinary
Reference39 articles.
1. Manohar, S. and Leung, N.R. (2018) Cisplatin nephrotoxicity: A review of the literature. J. Nephrol., 31(1): 15–25. 2. Volarevic, V., Djokovic, B., Jankovic, M.G., Harrell, C.R., Fellabaum, C., Djonov, V. and Arsenijević, N. (2019) Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. J. Biomed. Sci., 26(1): 25. 3. McSweeney, K.R., Gadanec, L.K., Qaradakhi, T., Ali, B.A., Zulli, A. and Apostolopoulos, V. (2021) Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers (Basel), 13(7): 1572. 4. Achkar, I.W., Abdulrahman, N., Al-Sulaiti, H., Joseph, J.M., Uddin, S. and Mraiche, F. (2018) Cisplatin based therapy: The role of the mitogen activated protein kinase signaling pathway. J. Transl. Med., 16(1): 96. 5. Makovec, T. (2019) Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol. Oncol., 53(2): 148–158.
|
|